After a median follow-up of 5 years, the aromatase inhibitor, anastrozole decreased the incidence of breast cancer in high-risk postmenopausal women by 53% compared to women receiving a placebo.
ABSTRACT & COMMENTARY
Anastrozole: Effective Chemoprevention of Breast Cancer in Postmenopausal Women
May 1, 2014